JOP20200093A1 - طريقة لإنتاج مشتق ثيازول - Google Patents

طريقة لإنتاج مشتق ثيازول

Info

Publication number
JOP20200093A1
JOP20200093A1 JOP/2020/0093A JOP20200093A JOP20200093A1 JO P20200093 A1 JOP20200093 A1 JO P20200093A1 JO P20200093 A JOP20200093 A JO P20200093A JO P20200093 A1 JOP20200093 A1 JO P20200093A1
Authority
JO
Jordan
Prior art keywords
formula
producing
thiazole derivative
represented
compound represented
Prior art date
Application number
JOP/2020/0093A
Other languages
English (en)
Inventor
Tada Atsushi
Yanagisawa Arata
Taga Masashi
Sugita Takamasa
Mimura Akihiro
Aoki Masashi
Chujo Iwao
Original Assignee
Kyowa Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Kirin Co Ltd filed Critical Kyowa Kirin Co Ltd
Publication of JOP20200093A1 publication Critical patent/JOP20200093A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

يتعلق الاختراع بطريقة لإنتاج مشتق ثيازول يتم تمثيله بواسطة الصيغة(I)، له عمل مضاد لمستقبل أدينوزين A2A ويعد مفيدًا باعتباره عاملاً علاجيًا لـ، على سبيل المثال، داء باركنسون، اضطرابات النوم، المقاومة المسكنة للمواد الأفيونية، الصداع النصفي، اضطراب الحركة، الاكتئاب، اضطراب القلق وما شابه. كما يتم أيضًا توفير طريقة إنتاج لمركب يتم تمثيلة بواسطة الصيغة(ج)، التي تحتوي على (1) خطوة إحداث تفاعل مركب يتم تمثيله بواسطة الصيغة(أ) ومركب يتم تمثيله بواسطة الصيغة(ب)، وما شابه: (حيث تمثل R1 الفوريل، تكون R4 و R5 و R6 نفسها أو مختلفة وتميل كل واحدة منها ألكيل أو أريل أدنى، تمثل R2 بيريديل أو تيترا هيدرو بيرانيل، وتمثل X1 هالوجين).
JOP/2020/0093A 2015-01-09 2020-05-03 طريقة لإنتاج مشتق ثيازول JOP20200093A1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015002964 2015-01-09

Publications (1)

Publication Number Publication Date
JOP20200093A1 true JOP20200093A1 (ar) 2020-05-03

Family

ID=56356063

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2016/0004A JO3546B1 (ar) 2015-01-09 2016-01-07 طريقة لإنتاج مشتق ثيازول
JOP/2020/0093A JOP20200093A1 (ar) 2015-01-09 2020-05-03 طريقة لإنتاج مشتق ثيازول

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JOP/2016/0004A JO3546B1 (ar) 2015-01-09 2016-01-07 طريقة لإنتاج مشتق ثيازول

Country Status (24)

Country Link
US (3) US10214523B2 (ar)
EP (2) EP3242877B1 (ar)
JP (2) JP6770962B2 (ar)
CN (1) CN107108602B (ar)
AR (1) AR103380A1 (ar)
AU (1) AU2016205657B2 (ar)
BR (1) BR112017014179A2 (ar)
CA (2) CA3080031C (ar)
CL (1) CL2017001695A1 (ar)
CO (1) CO2017006204A2 (ar)
DK (1) DK3242877T3 (ar)
ES (1) ES2861050T3 (ar)
HR (1) HRP20210385T1 (ar)
HU (1) HUE053567T2 (ar)
IL (2) IL252906B (ar)
JO (2) JO3546B1 (ar)
MX (2) MX379107B (ar)
PL (1) PL3242877T3 (ar)
PT (1) PT3242877T (ar)
RS (1) RS61570B1 (ar)
RU (2) RU2020141085A (ar)
SI (1) SI3242877T1 (ar)
TW (2) TWI732748B (ar)
WO (1) WO2016111381A1 (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3546B1 (ar) * 2015-01-09 2020-07-05 Kyowa Kirin Co Ltd طريقة لإنتاج مشتق ثيازول
CN109293652B (zh) * 2017-07-24 2021-10-22 四川科伦博泰生物医药股份有限公司 一种取代的噻唑衍生物及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE445350B (sv) * 1978-04-14 1986-06-16 Roussel Uclaf Oximderivat av 3-azidometyl-7-amino-tiazolyl-acetamido-cefalosporansyra och dess anvendning som antibiotika
JP4638355B2 (ja) * 2003-12-26 2011-02-23 協和発酵キリン株式会社 チアゾール誘導体
CN101031555A (zh) 2004-07-27 2007-09-05 安斯泰来制药有限公司 具有vap－1抑制活性的噻唑衍生物
EP1894930A4 (en) 2005-06-23 2010-06-23 Kyowa Hakko Kirin Co Ltd THIAZOLE DERIVATIVE
US7928098B2 (en) 2005-08-02 2011-04-19 Kyowa Hakko Kirin Co., Ltd. Therapeutic and/or preventive agents for a sleep disorder
WO2007024863A2 (en) 2005-08-22 2007-03-01 Melior Discovery, Inc. Methods and formulations for modulating lyn kinase activity and treating related disorders
CN101228143A (zh) * 2005-08-31 2008-07-23 安斯泰来制药株式会社 噻唑衍生物
WO2007026761A1 (ja) * 2005-08-31 2007-03-08 Astellas Pharma Inc. チアゾール誘導体
TWI473614B (zh) 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
KR20110040856A (ko) 2008-07-23 2011-04-20 교와 핫꼬 기린 가부시키가이샤 편두통 치료제
TWI548411B (zh) 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
UA110097C2 (uk) * 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
UA113383C2 (xx) 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів
WO2012027965A1 (en) * 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
JP6266270B2 (ja) 2013-05-20 2018-01-24 セイコーインスツル株式会社 運動フォーム解析装置および運動フォーム解析方法
JO3546B1 (ar) 2015-01-09 2020-07-05 Kyowa Kirin Co Ltd طريقة لإنتاج مشتق ثيازول

Also Published As

Publication number Publication date
CO2017006204A2 (es) 2017-11-10
HRP20210385T1 (hr) 2021-04-16
CA3080031C (en) 2022-04-12
JO3546B1 (ar) 2020-07-05
AU2016205657A1 (en) 2017-07-13
US20190144438A1 (en) 2019-05-16
EP3242877B1 (en) 2020-12-16
AR103380A1 (es) 2017-05-03
CA2972746C (en) 2020-07-07
US20200216438A1 (en) 2020-07-09
US10618894B2 (en) 2020-04-14
RU2020141085A (ru) 2021-02-10
EP3822269A1 (en) 2021-05-19
DK3242877T3 (da) 2021-03-08
AU2016205657B2 (en) 2019-01-17
IL252906B (en) 2020-03-31
US10894790B2 (en) 2021-01-19
BR112017014179A2 (pt) 2018-03-06
TW202035397A (zh) 2020-10-01
JP2018501282A (ja) 2018-01-18
CN107108602A (zh) 2017-08-29
MX2017009008A (es) 2017-09-27
RU2738937C2 (ru) 2020-12-18
MX379107B (es) 2025-03-10
EP3242877A4 (en) 2018-10-17
RS61570B1 (sr) 2021-04-29
CL2017001695A1 (es) 2018-03-23
EP3242877A1 (en) 2017-11-15
CA2972746A1 (en) 2016-07-14
TWI732748B (zh) 2021-07-11
IL272811A (en) 2020-04-30
TW201639835A (zh) 2016-11-16
US20180002326A1 (en) 2018-01-04
ES2861050T3 (es) 2021-10-05
PT3242877T (pt) 2021-03-11
CA3080031A1 (en) 2016-07-14
MX2021000711A (es) 2021-03-25
CN107108602B (zh) 2021-08-03
IL252906A0 (en) 2017-08-31
JP7068402B2 (ja) 2022-05-16
HUE053567T2 (hu) 2021-07-28
JP6770962B2 (ja) 2020-10-21
JP2020193209A (ja) 2020-12-03
US10214523B2 (en) 2019-02-26
SI3242877T1 (sl) 2021-04-30
PL3242877T3 (pl) 2021-05-31
RU2017128217A (ru) 2019-02-11
WO2016111381A1 (en) 2016-07-14
TWI729810B (zh) 2021-06-01
RU2017128217A3 (ar) 2019-02-11

Similar Documents

Publication Publication Date Title
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
ZA201507958B (en) New somatostatin receptor subtype 4 (sstr4)agonists
GEAP202014908A (en) Allosteric modulators of nicotinic acetylcholine receptors
CY1118848T1 (el) Ενωσεις 1,3-οξαζολιδινης ή 1,3-οξαζινανης ως ανταγωνιστες υποδοχεα ορεξινης
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
EA201790519A1 (ru) Терапевтические соединения в качестве ингибиторов рецептора орексина-1
PH12017501043A1 (en) 2-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
EA201791367A1 (ru) Соединения 2,3,4,5-тетрагидропиридин-6-амин и 3,4-дигидро-2h-пиррол-5-амин - ингибиторы бета-секретазы
CY1125225T1 (el) 6-μελεις αζα-ετεροκυκλοι που περιεχουν eνωσεις τροποποιησης υποδοχεα δελτα-οπιοειδων, μεθοδοι χρησης και δημιουργιας αυτων
MA32943B1 (ar) بيبيريدين سبيرو بيروليديون و بيبيريدينون مستبدلة ، إعدادها واستخدامها في العلاج
MA39171A1 (fr) Dérivés d'hydroxy formamide et leur utilisation
EA201891710A1 (ru) Терапевтические соединения
MX2016008898A (es) Antagonistas selectivos de nr2b.
MX2016008536A (es) Derivados de fluoro-naftilo.
BR112017019685A2 (pt) composto, composição farmacêutica, uso de um composto ou um sal ou um solvato farmaceuticamente aceitável do mesmo, e, método para tratamento de uma doença ou condição
MX369345B (es) Procesos para la preparacion de analogos de oxitocina.
JOP20200093A1 (ar) طريقة لإنتاج مشتق ثيازول
MX2015008733A (es) Derivados de 1,2,3-triazol-4-amina para el tratamiento de enfermedades y transtornos relacionados con receptores sigma.
BR112016021910A2 (pt) Processo de preparação de 3-(3-(4-(1-aminociclobutil)fenil)-5-fenil-3h-imidazo[4,5-b]piridin-2-il)piridin-2-amina
TW201612169A (en) (R)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
EA201692227A1 (ru) Производные сложных аминоэфиров
MX2019014272A (es) Compuestos policiclicos y usos de los mismos.
MX2018004256A (es) Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos.
CY1110087T1 (el) Μεθοδοι παρασκευης ενωσεων που περιεχουν πυρραζολιο